2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-174649
    Human IGFBP4 mRNA 98%
    Human IGFBP4 mRNA encodes the human insulin like growth factor binding protein 4 (IGFBP4) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP4 can bind both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors.
    Human IGFBP4 mRNA
  • HY-174650
    Human IGFBP3 mRNA 98%
    Human IGFBP3 mRNA encodes the human insulin like growth factor binding protein 3 (IGFBP3) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP3 can form a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.
    Human IGFBP3 mRNA
  • HY-174651
    Human IGFBP2 mRNA 98%
    Human IGFBP2 mRNA encodes the human insulin like growth factor binding protein 2 (IGFBP2) protein, is one of six similar proteins that bind insulin-like growth factors I and II (IGF-I and IGF-II).
    Human IGFBP2 mRNA
  • HY-174652
    Human IGFBP1 mRNA 98%
    Human IGFBP1 mRNA encodes the human insulin like growth factor binding protein 1 (IGFBP1) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP1 is important in cell migration and metabolism.
    Human IGFBP1 mRNA
  • HY-174653
    Human IGF2 mRNA 98%
    Human IGF2 mRNA encodes the human insulin like growth factor 2 (IGF2) protein, a member of the insulin family of polypeptide growth factors. IGF2 plays a key role in regulating fetoplacental development and also involves in tissue differentiation.
    Human IGF2 mRNA
  • HY-174654
    Human IGF1R mRNA 98%
    Human IGF1R mRNA encodes the human insulin like growth factor 1 receptor (IGF1R) protein. IGF1R plays a critical role in transformation events.
    Human IGF1R mRNA
  • HY-174668
    Human HNF1B mRNA 98%
    Human HNF1B mRNA encodes the human HNF1 homeobox B (HNF1B) protein, a member of the homeodomain-containing superfamily of transcription factors. HNF1B has been shown to function in nephron development, and regulates development of the embryonic pancreas.
    Human HNF1B mRNA
  • HY-174773
    Human BTC mRNA 98%
    Human BTC mRNA encodes the human betacellulin (BTC) protein, a member of the epidermal growth factor family. BTC promotes pancreatic cell proliferation and insulin secretion, as well as retinal vascular permeability.
    Human BTC mRNA
  • HY-174805
    THRβ receptor agonist-2 2411677-11-5
    THRβ receptor agonist-2 (Example 7-4) is a THRβ receptor agonist. THRβ receptor agonist-2 can be used for research of liver disorder or a cardiometabolic disease.
    THRβ receptor agonist-2
  • HY-174829
    7,4'-Dimethoxy-3-hydroxyflavone 13198-99-7 98%
    7,4'-Dimethoxy-3-hydroxyflavone is an orally active PAR4 antagonist. 7,4'-Dimethoxy-3-hydroxyflavone inhibits PAR4-mediated human platelet aggregation with an IC50 of 1.4 μM. 7,4'-Dimethoxy-3-hydroxyflavone inhibits PAR4-mediated human platelet aggregation and PAR4 signaling pathways, including NF-κB, Ca2+/protein kinase C, Akt, ERK and p38. 7,4'-Dimethoxy-3-hydroxyflavone prevents vascular PAR4 expression, endothelial dysfunction and ameliorates oxidative stress in Streptozotocin (STZ) (HY-13753)-induced diabetic mice. 7,4'-Dimethoxy-3-hydroxyflavone prevents thrombosis in mice without affecting bleeding time[1][2].
    7,4'-Dimethoxy-3-hydroxyflavone
  • HY-174832
    DPP-4-IN-16
    DPP-4-IN-16 (Compound 92) is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor (IC50=0.8 nM). DPP-4-IN-16 inhibits DPP-4-mediated degradation of incretins (e.g., GLP-1 and GIP) to promote insulin secretion and reduce blood glucose. DPP-4-IN-16 is promising for research of type 2 diabetes.
    DPP-4-IN-16
  • HY-175016
    NADH-IN-3
    NADH-IN-3 (Compound C4-1) is a NADH inhibitor with a MIC of 4 μg/mL (13.042 μM) for type II NADH dehydrogenase of Mycobacterium tuberculosis (Mtb). NADH-IN-3 significantly interrupts ATP synthesis, shows potent inhibitory effects against mono (Rifampicin (HY-B0272) and Isoniazid (HY-B0329)) and multi drug-resistant (Mtb) strains and an anti-bactericidal activity against HepG2 cells with low cytotoxicity (SI: 16.52).
    NADH-IN-3
  • HY-175189
    PCSK9-IN-33
    PCSK9-IN-33 (Compound 1'f) is a PCSK9 inhibitor with an IC50 of 161 nM. PCSK9-IN-33 can be used for hypercholesterolemia research.
    PCSK9-IN-33
  • HY-175309
    URAT1-IN-14 2516232-89-4 98%
    URAT1-IN-14 is a potent and orally active Urate transporter 1 (URAT1) inhibitor. URAT1-IN-14 inhibits the human URAT1 in HEK293 cells with an IC50 of 0.72 μM. URAT1-IN-14 exhibits low cytotoxic in Hep-G2 cells. URAT1-IN-14 shows urate-lowering effect in hyperuricemia mouse models. URAT1-IN-14 can be used for the study of hyperuricemia and gout.
    URAT1-IN-14
  • HY-175349
    Tyrosinase-IN-43 98%
    Tyrosinase-IN-43 (Compound 12j) is a competitive Tyrosinase inhibitor with an IC50 of 10.49 ?μM for tyrosinase. Tyrosinase-IN-43 has significant antioxidant activity. Tyrosinase-IN-43 can be used for hyperpigmentation-related complications such as melasma, freckles, age spots and post-inflammatory hyperpigmentation research.
    Tyrosinase-IN-43
  • HY-175423
    DHODH-IN-30
    DHODH-IN-30 (compound 4g) is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC50 of 32 nM. DHODH-IN-30 exhibits protective effects against oxidative stress.
    DHODH-IN-30
  • HY-175590
    DPP-4-IN-17
    DPP-4-IN-17 is an orally active and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with an IC50 value of 0.12 nM. DPP-4-IN-17 increases the enzyme's Km value (75.73 μM vs. 27.18 μM of substrate alone) and reduces catalytic efficiency. DPP-4-IN-17 reduces blood glucose levels and reverses weight loss in Streptozotocin (STZ) (HY-13753)/Nicotinamide (NA) (HY-B0150)-induced diabetic rats. DPP-4-IN-17 can be used for the study of type 2 diabetes mellitus (T2DM).
    DPP-4-IN-17
  • HY-175725
    NR4A1 agonist 1 1825366-87-7
    NR4A1 agonist 1 is a NR4A1 agonist with a Ki value of 2.96 μM. NR4A1 agonist 1 exhibits lipid-lowering activity in 3T3-L1 adipocytes, with an EC50 of 0.13 μM, significantly decreasing triglyceride (TG) accumulation and lipid droplet accumulation. NR4A1 agonist 1 can be used for the study of obesity.
    NR4A1 agonist 1
  • HY-17582R
    Decloxizine (Standard) 3733-63-9
    Decloxizine (UCB-1402; NSC289116) (Standard) is the analytical standard of Decloxizine. This product is intended for research and analytical applications.Decloxizine is an orally active bronchodilator that can penetrate the blood-brain barrier. Decloxizine is a piperazine-type H1 histamine receptor antagonist. Decloxizine selectively blocks H1 histamine receptors, inhibiting histamine-induced capillary dilation, edema, and itching. Decloxizine has some 5-HT2 receptor antagonistic activity. Decloxizine can be used in studies of urticaria, allergic rhinitis, and bronchial asthma.
    Decloxizine (Standard)
  • HY-175862
    ALR2-IN-9 2135481-84-2 98%
    ALR2-IN-9 is a potent ALR2 inhibitor (IC50 = 21.8 nM) with excellent antioxidant activity (EC50 for DPPH radical scavenging = 2.8 μM). ALR2-IN-9 interacts directly with Reactive Oxygen Species (ROS)/Reactive Nitrogen Species (RNS) and interrupts the free radical chain reactions, and as an endogenous enzymatic antioxidant regulator, which regulates enzyme functions of CAT and SOD. ALR2-IN-9 regulates PI3K/Akt/Nrf2 pathway to attenuate hyperglycemia-mediated mitochondrial superoxide overproduction in vitro, and ameliorates CuSO4- and H2O2-induced oxidative stress in vivo. ALR2-IN-9 prolongs lifespan of C. elegans via the regulation of stress response genes such as PMK-1. ALR2-IN-9 is a promising anti-aging drug candidate. ALR2-IN-9 can be used for diabetic complication research.
    ALR2-IN-9
Cat. No. Product Name / Synonyms Application Reactivity